Quantcast

Industry news that matters to you.  Learn more

Covance BioPathways ADAPT2011 Slides

Last week at the ADAPT2011 conference during the Biomarker Discovery Informatics Track, Covance announced a new resource called BioPathways that enables scientists to search biological and disease pathways and rapidly identify validated assays and commercially available antibodies.

Covance BioPathways for Biomarker Discovery

Covance has launched a free resource on Covance.com to enable scientists to search biological and disease pathways and rapidly identify validated assays and commercially available antibodies. To describe Covance BioPathways and it’s application to biomarker discovery, Covance will be sponsoring a presentation during the Biomarker Discovery Informatics Track at the upcoming Cambridge Healthtech Institute ADAPT Congress. The ADAPT presentation is scheduled in Philadelphia on September 9th, 2011.

CROs Join with MJFF for Parkinson’s Biomarker Research

Covance, Parexel and Epitomics are working with the Michael J Fox Foundation for Parkinson’s Research (MJFF) to develop biomarker candidates.

Initiation of the projects is part of efforts by MJFF to progress biomarker research. MJFF said there is “urgent need for an orchestrated, fieldwide strategy to drive tangible progress” in the sector and contract research organisations (CRO) have a role to play in this initiative.

Michael J. Fox Foundation Announces $1.1 Million to Advance Leading Biomarker Candidates for Parkinson’s Disease

The Michael J. Fox Foundation for Parkinson’s Research today announced nearly $1.1 million for projects aimed at advancing the development of leading biomarker candidates for Parkinson’s disease. The discovery and validation of biomarkers is of critical importance to increasing the speed and efficiency of PD therapeutic development, allowing scientists and clinicians to more accurately identify appropriate subjects for clinical studies, measure disease progression and monitor treatment effects in clinical trials.

Biomarkers in Demand but CROs Cautious, Study

Demand for biomarker analysis is strong, but the pace of technological change is causing an investment headache for CROs according to a new report by Industry Standard Research (ISR). The research, “The State of Biomarkers in Drug Development,” examined the attitudes of 37 top pharmaceutical and biotechnology companies with regard to the use of biomarkers in clinical development.